“O

h crap,” Kevin Costa thought. A biomechanical engineer, he had labored for months to create miniature hearts, starting with a slurry of stem cells from rats and then coaxing them with chemicals in comfy little lab dishes not only to turn into specialized cardiac cells but also to gallivant around until they formed a three-dimensional, mini-me organ.

As he peered into a jury-rigged beaker held together with binder clips, however, Costa didn’t need a microscope — heck, he didn’t even need reading glasses — to see that something had gone crushingly wrong. The little heart had a hole at one end.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy